Modulation of antibody specificity by tailoring the affinity to cognate antigens

• US 20060121042A1
• Filed: 10/27/2005
• Published: 06/08/2006
• Est. Priority Date: 10/27/2004
• Status: Abandoned Application

• Current Assignee: Medimmune LLC (Astrazeneca PLC)
• Original Assignee: Medimmune Incorporated (Astrazeneca PLC)
• Inventors: Dall'Acqua, William, Damschroder, Melissa, Kinch, Michael S., Carles-Kinch, Kelly
• Application Number:
  US11/259,133
• Publication Number:
  US 20060121042A1
• Time in Patent Office: Days
• US Class Current: 424/155.100
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/005 constructed by phage libraries
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of various disorders associated with aberrant expression and/or activity of one or more Eph receptor tyrosine kinase family members and/or one or more Eph receptor ligands, particularly the Ephrins. In particular, the invention provides methods for the treatment, management, prevention and/or amelioration of a disorder associated with aberrant expression and/or activity(ies) of one or more Eph receptors and/or one or more Ephrins, the method comprising administering to a subject in need thereof an effective amount of one or more Eph/Ephrin Modulators. The present invention further relates to methods of modulating antibody specificity by tailoring the affinity to cognate antigens.

Claims

1. A method of tailoring the specificity of a pan-specific antibody that specifically binds at least two members within a receptor tyrosine kinase (RTK) family, said method comprising randomizing each amino acid of the CDRs of said pan-specific antibody;

generating a library comprising said randomized CDRs; and

screening said library for clones with altered affinity for a desired receptor(s).

2. The method of claim 1, wherein said receptor tyrosine kinase family is selected from the group consisting of a class I RTK, a class II RTK, a class III RTK, a class IV RTK, a class V RTK, a class VI RTK, a class VII RTK, a class VIII RTK, a class IX RTK, a class X RTK, a class XI RTK, a class XII RTK, a class XIII RTK, a class XIV RTK, a class XVI RTK, a class XVII RTK, a class XVIII RTK, and a class XIX RTK.

3. The method of claim 1, wherein said receptor tyrosine kinase family is the Eph family of receptors.

4. The method of claim 1, wherein said library is a prokaryotic library or a eukaryotic library.

5. The method of claim 4, wherein said library is an expression library or a display library.

6. The method of claim 5, wherein said library is a prokaryotic phage expression library.

7. An antibody that specifically binds the Eph receptor epitope to which monoclonal antibody GEA44 binds.

8. An antibody that has been tailored to specifically bind desired combinations of members of the Eph family of receptors, said binding being represented by the following formulas:

EphA(x)+[EphB(y)](n₂);

EphA(x)+[EphA(x)](n₁);

EphB(y)+[EphB(y)](n₂);

EphB(y)+[EphA(x)](n₁) or [EphA(x)](n₁)+[EphB(y)](n₂), wherein (x) is 1, 2, 3, 4, 5, 6, 7, 8, or 10, (y) is 1, 3, 4, 5 or 6, (n₁) is a multiple of 0-8, and (n₂) is a multiple of 0-5.

9. The antibody of claim 8, with the proviso that said antibody is not D7, EA2, EA5, B210, B233, or B208.

10. The antibody of claim 8, wherein said antibody is an agonistic antibody.

11. The antibody of claim 8, wherein said antibody is selected from the group consisting of 1A4, 1B10, 1D11, 1G11, 2C9 , 11H1, 3A12, 3C6, 6B7, and 8B4.

12. The antibody of claim 8, wherein said antibody specifically binds at least two members of the Eph family of receptors.

13. The antibody of claim 8, wherein said antibody specifically binds at least three members of the Eph family of receptors.

14. The antibody of claim 8, wherein said antibody specifically binds at least four members of the Eph family of receptors.

15. The antibody of claim 8, wherein said antibody specifically binds at least five members of the Eph family of receptors.

16. The antibody of claim 8, wherein said antibody specifically binds at least six members of the Eph family of receptors.

17. The antibody of claim 8, wherein said antibody specifically binds at least seven members of the Eph family of receptors.

18. The antibody of claim 8, wherein said antibody specifically binds at least eight members of the Eph family of receptors.

19. The antibody of claim 8, wherein said antibody specifically binds at least nine members of the Eph family of receptors.

20. The antibody of claim 8, wherein said antibody specifically binds at least ten members of the Eph family of receptors.

21. The antibody of claim 8, wherein said antibody specifically binds at least eleven members of the Eph family of receptors.

22. The antibody of claim 8, wherein said antibody specifically binds at least twelve members of the Eph family of receptors.

23. The antibody of claim 8, wherein said antibody specifically binds at least thirteen members of the Eph family of receptors.

24. The antibody of claim 8, wherein said antibody specifically binds at least fourteen members of the Eph family of receptors.

25. The antibody of claim 8, wherein said antibody specifically binds at least fifteen members of the Eph family of receptors.

26. The antibody of claim 8, wherein said antibody specifically binds at least sixteen members of the Eph family of receptors.

27. The antibody of claim 8, wherein said antibody specifically binds at least two members of the EphA family of receptors.

28. The antibody of claim 8, wherein said antibody specifically binds at least three members of the EphA family of receptors.

29. The antibody of claim 8, wherein said antibody specifically binds at least four members of the EphA family of receptors.

30. The antibody of claim 8, wherein said antibody specifically binds at least five members of the EphA family of receptors.

31. The antibody of claim 8, wherein said antibody specifically binds at least six members of the EphA family of receptors.

32. The antibody of claim 8, wherein said antibody specifically binds at least seven members of the EphA family of receptors.

33. The antibody of claim 8, wherein said antibody specifically binds at least eight members of the EphA family of receptors.

34. The antibody of claim 8, wherein said antibody specifically binds at least nine members of the EphA family of receptors.

35. The antibody of claim 8, wherein said antibody specifically binds all members of the EphA family of receptors.

36. The antibody of claim 8, wherein said antibody specifically binds at least two members of the EphB family of receptors.

37. The antibody of claim 8, wherein said antibody specifically binds at least three members of the EphB family of receptors.

38. The antibody of claim 8, wherein said antibody specifically binds at least four members of the EphB family of receptors.

39. The antibody of claim 8, wherein said antibody specifically binds at least five members of the EphB family of receptors.

40. The antibody of claim 8, wherein said antibody specifically binds at least six members of the EphB family of receptors.

41. The antibody of claim 8, wherein said antibody specifically binds all members of the EphB family of receptors.

42. The antibody of claim 8, wherein said antibody is human or humanized.

43. The antibody of claim 8, wherein said antibody specifically binds to a first Eph receptor with a first affinity, and specifically binds to at least a second Eph receptor with an affinity that is equal to, increased, and/or decreased as compared to said first affinity.

44. The antibody of claim 43, wherein said affinity of said at least a second Eph receptor is decreased.

45. The antibody of claim 43, wherein said affinity that is increased and/or decreased is increased and/or decreased by at least 1.1 fold, at least 1.2 fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, at least 10 fold, at least 15 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 200 fold, at least 300 fold at least 400 fold, at least 500 fold, or at least 1000 fold.

46. The antibody of claim 43, wherein said first affinity is a K_D of at least about 1×

10⁶ M<sup>−

1</sup>, at least about 1×

10⁷ M<sup>−

1</sup>, at least about 1×

10⁸ M<sup>−

1</sup>, at least about 1×

10⁹ M<sup>−

1</sup>, at least about 1×

10¹⁰ M<sup>−

1</sup>, at least about 1×

10¹¹ M<sup>−

1</sup>, at least about 1×

10¹² M<sup>−

1</sup>, at least about 1×

10¹³ M<sup>−

1</sup>, at least about 1×

10¹⁴ M<sup>−

1</sup>, or at least about 1×

10¹⁵ M<sup>−

1</sup>.

47. The antibody of claim 43, wherein said first affinity is a K_D of between about 1×

10⁶ M<sup>−

1</sup> and about 1×

10⁷ M<sup>−

1</sup>, between about 1×

10⁷ M<sup>−

1</sup> and about 1×

10⁸ M<sup>−

1</sup>, between about 1×

10⁸ M<sup>−

1</sup> and about 1×

10⁹ M<sup>−

1</sup>, between about 1×

10⁹ M<sup>−

1</sup> and about 1×

10¹⁰ M<sup>−

1</sup>, between about 1×

10¹⁰ M<sup>−

1</sup> and about 1×

10¹¹ M<sup>−

1</sup>, between about 1×

10¹¹ M<sup>−

1</sup> and about 1×

10¹² M<sup>−

1</sup>, between about 1×

10² M<sup>−

1</sup> and about 1×

10¹³ M<sup>−

1</sup>, between about 1×

10¹³ M<sup>−

1</sup> and about 1×

10¹⁴ M<sup>−

1</sup>, or between about 1×

10¹⁴ M<sup>−

1</sup> and about 1×

10⁵ M<sup>−

1</sup>.

48. A cell line which produces the antibody of claim 8.

49. A method for treating or preventing a disorder associated with aberrant Eph receptor or Ephrin expression in a subject comprising administering to the subject in need of said treating or preventing an effective amount of Eph/Ephrin Modulator.

50. The method of claim 49, wherein said Eph/Ephrin Modulator modulates at least one or more Eph receptors and at least one or more Ephrins.

51. The method of claim 49, wherein said Eph/Ephrin Modulator modulates the expression of at least two or more Eph receptors.

52. The method of claim 49, wherein said Eph/Ephrin Modulator modulates the activity of at least two or more Ephrins.

53. The method of claim 50, wherein said Eph receptors are selected from the group consisting of EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4, EphB5 and EphB6.

54. The method of claim 49, wherein said Eph/Ephrin Modulator modulates the expression of at least two or more Ephrins.

55. The method of claim 49, wherein said Eph/Ephrin Modulator modulates the activity of at least two or more Ephrins.

56. The method of claim 49, wherein said Ephrins are selected from the group consisting of EphrinA1, EphrinA2, EphrinA3, EphrinA4, EphrinA5, EphrinB1, EphrinB2 and EphrinB3.

57. The method of claim 49, wherein said Eph/Ephrin Modulator is the antibody of claim 8.

58. The method of claim 49, wherein the disorder to be treated is cancer.

59. The method of claim 58, wherein the cancer is cancer of the liver, lung, kidney, prostate, pancreas, testes, colon, stomach, endometrium, ovary, breast, bone, soft tissues, uterus, cervix, synovial fluid, parotid gland, esophagus, skin, rectum, and thyroid gland.

60. The method of claim 49, wherein the disorder to be treated is selected from the group consisting of PLCH, GVHD, primary congestive dilated cardiomyopathy, granulomatous myocarditis, chronic pancreatitis, cirrhosis of the liver, Hashimoto'"'"'s Thyroiditis, Alzheimer'"'"'s disease, acute cholecystitis, Crohn'"'"'s disease, diverticulitis, ulcerative colitis and psoriasis.

61. The method of claim 49 wherein said Eph/Ephrin Modulator inhibits the production of VEGF.

62. The method of claim 58 wherein said Eph/Ephrin Modulator inhibits the proliferation of cancer cells.

63. The method of claim 58 wherein said Eph/Ephrin Modulator inhibits the migration of cancer cells.

64. The method of claim 58 wherein said Eph/Ephrin Modulator inhibits the invasion of cancer cells.